Tag: neurotology

March 11, 2019

Auris Medical Announces Publication of AM-111 Phase 3 Results in Peer-Reviewed Scientific Journal

Auris Medical Holding AG (NASDAQ:EARS) has announced the publication of an article that details the outcomes from the HEALOS Phase...
January 23, 2019

Auris Medical Announces Publication of New Data Highlighting the Role of Betahistine

Auris Medical (NASDAQ:EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central...
November 20, 2018

Auris Medical Shares Positive FDA Meeting Results

The regulatory agency supports Auris’ plan to conduct multiple doses of AM-201 in a Phase 1 trial with healthy volunteers....
November 20, 2018

Auris Medical Announces Results of Pre-IND Meeting With FDA For AM-201 Program

Auris Medical (NASDAQ:EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and mental...
August 30, 2018

Auris Medical Receives FDA Guidance at Type C Meeting for AM-111 in the Treatment of Sudden Sensorineural Hearing Loss

Auris Medical (NASDAQ:EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and mental...